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Abstract
Understanding stem cell-differentiation at the molecular level is important for clinical applications of stem cells and for
finding new therapeutic approaches in the context of cancer stem cells. To investigate genome-wide changes involved in
differentiation, we have used immortalized neural stem cell (NSC) line (HB1.F3) and Olig2-induced NSC differentiation model
(F3.Olig2). Using microarray analysis, we revealed that Olig2-induced NSC differentiation involves downregulation of Wnt
pathway, which was further confirmed by TOPflash/FOPflash reporter assay, RT-PCR analysis, immunoblots, and
immunocytochemistry. Furthermore, we found that Olig2-induced differentiation induces the expression of Dickkopf-
1(Dkk1), a potent antagonist of Wnt signaling. Dkk1 treatment blocked Wnt signaling in HB1.F3 in a dosage-dependent
manner, and induced differentiation into astrocytes, oligodendrocytes, and neurons. Our results support cancer stem cell
hypothesis which implies that signaling pathway for self-renewal and proliferation of stem cells is maintained till the late
stage of differentiation. In our proposed model, Dkk1 may play an important role in downregulating self-renewal and
proliferation pathway of stem cells at the late stage of differentiation, and its failure may lead to carcinogenesis.
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Introduction
It has been widely accepted until recently that no new neurons
are generated after neurogenesis is completed during the early
embryonic development (i.e., there are no resident stem cells in the
nervous system) [1]. More recent studies, however, led to the
isolation of neural stem cells (NSCs) from the embryonic
mammalian central nervous system (CNS) [2–4], followed by the
isolation of NSCs from the adult mammalian CNS [5,6]. These
discoveries revealed the regenerative power of the CNS, which
may be used for therapeutic purposes [7].
Currently, there are four main strategies in NSCs and their
progenitor cell-based therapy: transplantation of oligodendrocyte
progenitor cells for treating myelin disorders; transplantation of
neuronal progenitor cells to treat diseases of discrete loss of a single
neuronal phenotype, such as Parkinson disease; implantation of
mixed progenitor pools to treat diseases resulting from the loss of
several phenotypes, such as spinal cord injury; mobilization of
endogenous neural progenitor cells to treat neurodegenerative
diseases [8]. Despite significant progress that has been made for
clinical application of NSCs, key questions about global perspec-
tives for the differentiation pathway remain to be answered
including molecular determinants of neural and glial fates and
distinctive stages of differentiation [9].
Understanding differentiation is important for at least two
reasons. Firstly, differentiation is a process of acquiring specific
functions of committed cells. Therefore, understanding each step
of differentiation, and characterizing differentiation phenotypes
are the basis of stem cell engineering. Future stem cell research is
likely to focus on improving the ability to guide the differentiation
of stem cells and to control their survival and proliferation for
clinical application [10]. Secondly, understanding differentiation
may provide an important clue for treating cancers. According to
the newly emerging cancer stem cell hypothesis, tumors seem to
arise from small populations of cancer stem cells that originate
from the transformation of normal stem cells [11]. In this
hypothesis, a tumor can be viewed as an aberrant organ initiated
by a cancer stem cell that undergoes processes analogous to the
self-renewal and differentiation of normal stem cells [12].
Although similar to normal stem cells in many ways, cancer stems
cells are critically different in that their transit-amplifying progeny
do not mature and die as do the progeny of normal stem cells
(maturation arrest) [13]. Therefore, understanding differentiation
may ultimately lead to the development of differentiation therapy,
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allowing the cancer cells to differentiate and die eventually [14].
To identify genes and pathways that could play a role in the
differentiation of NSCs, we performed microarray analysis using
immortalized neural stem cell line (HB1.F3) and its oligodendro-
cyte progeny (F3.Olig2) in which olig2 is over-expressed. It has
been shown that olig2 overexpression can induce the in vitro
differentiation of NSCs into mature oligodendrocytes [15].
HB1.F3 has the ability to self-renew and differentiate into cells
of neuronal and glial lineages in both in vivo and in vitro [16,17].
F3.Olig2 cells express oligodendrocyte markers and represent a
model of NSC differentiation (Fig. 1).
Results
Downregulation of Wnt pathway in F3.Olig2
Microarray analysis revealed global gene expression changes
between HB1.F3 and F3.Olig2; more than 60% of genes that are
present in HB1.F3 are absent in F3.Olig2. Since the global gene
expression changes violate basic assumptions of statistical analysis
of microarray data that most genes are not differentially expressed
[18], we have employed the knowledge-based Gene Set Enrich-
ment Analysis (GSEA) (Materials and Methods), instead of using
conventional statistical analysis such as t-test, to investigate
expression changes in functional groups of genes. Since the Wnt
pathway is known to be involved in neural stem cell-differentiation
in contra-acting ways (i.e., maintain stemness versus inducing
differentiation [19–21], the investigation of the microarray data
was focused on Wnt pathway-related gene sets. Using this method,
we identified significant enrichment of Wnt pathway genes, genes
upregulated by Wnt [22], and Wnt pathway target genes in
HB1.F3, an immortalized neural stem cell line (Fig. 2A–C) (see
Table S1, S2, S3 for detailed information). To obtain further
evidence that Wnt pathway is active in HB1.F3 and suppressed in
F3.Olig2, we transfected a transcription factor (TCF) reporter
gene (TOPflash) containing five optimal TCF-binding sites or the
mutant control plasmid (FOPflash) into HB1.F3 and F3.Olig2.
pRL-TK was included to normalize data for transfection efficiency
[23]. As shown in Fig. 2D, the reporter activity of Wnt pathway is
more than three times higher in HB1.F3 than in F3.Olig2. The
addition of dominant negative TCF plasmids (dnTCF) decreased
the reporter activity in HB1.F3 close to the level of F3.Olig2,
indicating that the Wnt activity in F3.Olig2 is at the background
level.
Validation of gene expression using semiquantitative RT-
PCR
As described above, both GSEA and the reporter assay revealed
that Wnt pathway is active in HB1.F3 and downregulated in
F3.Olig2. To further confirm these findings at the molecular level,
we performed semiquantitative RT-PCR analysis of Wnt pathway
components including 18 Wnt families, 4 Wnt receptors, 2 Wnt
co-receptors, 2 antagonists of Wnt signaling, and 2 target genes of
Wnt pathway. Most of Wnt genes which expressed in HB1.F3 are
suppressed in F3.Olig2, whereas only Wnt 10b gene is increased in
F3.Olig2 (Fig. 3A). Interestingly, Wnt7b is expressed only in
Figure 1. Expression of lineage-specific markers in HB1.F3 and F3.Olig2. Neural stem cell markers such as nestin [52] and CD133 [53] are
expressed only in HB1.F3 wherease oligodendrocytes markers such as O4 [54] and CNPase [55] are expressed only in F3.Olig2. Merged; markers with
DAPI, Bar=50 mm
doi:10.1371/journal.pone.0003917.g001
Olig2-Induced Differentiation
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F3.Olig2 and frizzled 5(FZD5) was not expressed in both HB1.F3
and F3.Olig2 (Fig. 3B). In accordance with GSEA results, Wnt
pathway target genes such as Axin2 [24] and c-myc [25] are
expressed only in HB1.F3 (Fig. 3C). On the other hand, Dickkopf-
1 (Dkk1), a secreted Wnt antagonist [26], is expressed only in
F3.Olig2 (Fig. 3D). Unlike other Wnt antagonists, the function of
Dkk1 is independent of Frizzled, and inhibits canonical Wnt
signaling by binding to LRP6 [27,28], the only Wnt co-receptor
expressed in F3.Olig2.
Levels of b-catenin and phosphor-b-catenin (p-b-
catenin), and their subcellular localization
Wnt signaling is transduced to b-catenin in cytoplasm, which
enters the nucleus and activate transcription of Wnt pathway target
genes with TCF [29]. On the other hand, phosphorylation of b-
cateninleads to ubiquitination and degradation ofb-catenin[30,31].
In HB1.F3, b-catenin is mainly localized in nucleus and p- b-catenin
(pS33/pS37/pT41) is not detected (Fig. 4A, B). In F3.Olig2, b-catenin
is mainly localized in cytoplasm, and p- b-catenin pS33/pS37/pT41)
is exclusively observed in nucleus (Fig. 4A, B). In immunoblot
Figure 2. Downregulation of Wnt pathway in F3.Olig2. GSEA shows that Wnt pathway genes (A), Wnt-responsive genes (B), and Wnt pathway
target genes (C) are enriched in HB1.F3. TOPFLASH/FOPflash reporter analysis (D) confirms that Wnt pathway activity in HB1.F3 is significantly higher
than that in F3.Olig2. The reporter activity in HB1.F3 was inhibited to the level of F3.Olig2 when HB1.F3 was co-transfected with ‘dominant negative’
(DN) TCF constructs. Data are means6S.D. of triplicate samples. A.U., Activity unit
doi:10.1371/journal.pone.0003917.g002
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F3.Olig2 and p- b-catenin (pS33/pS37/pT41) was detected only in
F3.Olig2. The level of GSK3b, which phosphorylates b-catenin on
S33/S37/T41 [32], is also increased in F3.Olig2.
Suppression of Wnt signaling and induction of
differentiation by Dkk1
As shown in Fig. 3D, Dkk1, a potent antagonist of Wnt
signaling, is expressed only in F3.Olig2. We also tested the effect of
Dkk1 on HB1.F3. When HB1.F3 cells were treated with Dkk1,
Wnt signaling in HB1.F3 was inhibited in a dosage-dependent
manner (Fig. 5A). Dkk1 treatment decreased the expression of c-
myc, a Wnt pathway target gene, in a dosage-dependent manner
(Fig. 5B). Dkk1 treatment also induced the expression of
oligodendrocyte markers such as Olig2 and CNPase in HB1.F3
(Fig. 5C). Furthermore, Dkk1 treatment induced differentiation of
HB1.F3 into astrocytes, neurons, and oligodendrocytes (Fig. 6, Fig.
S1). As for differentiation efficiency, astrocytes were the highest,
oligodendrocytes the second, and neurons the lowest.
Discussion
In the present study, we showed that Olig2-induced differen-
tiation of NSCs leads to downregulation of Wnt pathway, which is
known to regulate the balance between self-renewal and
differentiation in CNS [33]. Although Wnt signaling can
influence cell lineage decisions such as neural differentiation of
NSCs [19], differentiation of embryonic stem cells into dorsal
interneurons [34], and differentiation of NSCs into dopaminergic
neurons [21], Wnt signaling predominates in stem cell proli-
feration and neural stem cell expansion [20], and inhibits
differentiation [21,35].
Unlike these studies that focused on modulating Wnt signaling
and analyzing its effects on stem cells, we found, in the present
study, that the differentiation-inducing event (i.e., overexpression
of Olig2) may precede the downregulation of Wnt pathway.
We found that most of genes, receptors, co-receptors, and target
genes expressions were increased in HB1.F3, but that of Wnt
inhibitor was increased in F3.Olig2. And b-catenin was observed
in cytoplasm of F3.Olig2 and nucleus of HB1.F3, whereas p-b-
catenin was expressed only in the nucleus of F3.Olig2. This means
canonical Wnt pathway may be activated in HB1.F3, and
decreased in F3.Olig2.
Furthermore, we showed that the expression of Dkk1, a potent
antagonist of Wnt signaling, is induced in F3.Olig2. Dkk1
treatment blocks Wnt signaling in HB1.F3, and induces differen-
tiation into astrocytes, oligodendrocytes, and neurons. These
findings comply with previous findings that blocking Wnt pathway
induces differentiation [21], but not lineage-specific. It is generally
accepted that there is the balance between self-renewal and
differentiation [33], which may be manifested in two different
ways. When Olig2, a differentiation-inducing signal, was overex-
pressed, this led to lineage-specific differentiation of neural stem
cells and downregulation of Wnt pathway (i.e., self-renewal
pathway) as demonstrated by F3.Olig2. When HB1.F3 cells were
treated with Dkk1, a Wnt inhibitor, this led to downregulation of
Wnt pathway and lineage-non-specific differentiation.
According to previous findings, Dkk1 is a direct target of the b-
catenin/TCF transcription complex that mediates Wnt signaling
[36–38]. Although these studies indicate that Dkk1 forms a novel
feedback loop in Wnt signaling, our results suggest that the
expression of Dkk1 is induced by a different pathway in F3.Olig2
since Wnt signaling as well as Wnt genes and receptors are
suppressed in F3.Olig2. Previous reports showed that the
expression of Dkk1 can be induced, independent of Wnt signaling,
by differentiation-promoting reagents such as 1a, 25-dihydrox-
yvitamin D3 [39] and retinoic acids [40]. Dkk1 can be also
induced by p53 [41].
Evidences from our experiments provide a probable link
between stem cell maturation arrest and carcinogenesis at the
molecular level. According to cancer stem cell hypothesis,
tumors arise from maturation arrest of stem cells [42], which
implies that signaling pathway for self-renewal and proliferation
of stem cells is maintained till the late stage of differentiation. In
our proposed model (Fig. 6), Wnt signaling, which is important
for self-renewal and proliferation of NSCs, is turned off at the
late stage of differentiation by Dkk1, which is turned on not by
Wnt pathway but by a differentiation-related pathway. The
feasibility of this model is supported by experimental evidences
that Dkk1 is epigenetically silenced in many tumors including
gastrointestinal tumors [43,44], cervical cancers [45], leukemia
[46], and medulloblastoma [47]. Also, in HeLa cells, Dkk1 is
required for tumorigenicity [48]. Altogether, these evidences
may indicate that Dkk1 play an important role in downregulat-
ing self-renewal and proliferation pathway of stem cells at the
late stage of differentiation, and its failure may lead to
carcinogenesis.
Figure 3. RT-PCR analysis of Wnt pathway-related genes. A.
Most Wnt genes are overexpressed in HB1.F3 whereas the expression of
Wnt 10b is increased in F3.Olig2. Interestingly, Wnt7b is expressed only
in F3.Olig2. B. Except FZD5, all Wnt receptor and co-receptor genes that
are expressed in HB1.F3 are suppressed in F3.Olig2. C. Wnt pathway
target genes are expressed only in HB1.F3. D. Dkk1, a soluble Wnt
antagonist, is expressed only in F3.Olig2.
doi:10.1371/journal.pone.0003917.g003
Olig2-Induced Differentiation
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Cell lines
Stable clonal human NSC line, HB1.F3, was generated by
retroviral transduction of primary fetal human neural stem cells
(hNSCs) with an avian v-myc cell cycle regulatory gene as
previously reported (Kim et al, 2008; Production and character-
ization of immortal human neural stem cell line with multipotent
differentiation property [49]. F3.Olig2 was generated by overex-
pressing Olig2 in HB1.F3. Briefly, Olig2 cDNA was ligated into
multiple cloning sites of the retroviral vector pLHCX (Clontech,
Mountain View, CA). PA317 amphotropic packaging cell line was
infected with the recombinant retroviral vector, and the
supernatants from the packagaing cells were added to the
HB1.F3 cells. Stably transfected colonies were selected by
hygromycin resistance (Kim et al., in submission).
Cell Culture
HB1.F3 and F3.Olig2 cells were maintained in Dulbecco’s modified
Eagles medium (DMEM) supplemented with 5% fetal bovine serum
(FBS), 5% horse serum, and 50 mg/ml gentamycin at 37uCa n d5 %
CO2. Dkk1 was acquired from R&D system (1096-DK) and added to
HB1.F3 cells at a concentration from 25 ng/mL to 400 ng/mL. Dkk1-
treated HB1.F3 cells were harvested 6 hrs after treatment.
Microarray analysis
Five replicates of each cell line were used for isolating and
purifying RNA by Qiagen RNeasy kit. The resulting total RNA
samples were further assessed for integrity prior to chipping using
BioRad Experion System. Microarray experiments were per-
formed using Sentrix Human-6 Whole Genome Expression
BeadChips (Illumina), analyzing over 46,000 known genes, gene
candidates, and splice variants according to manufacturer’s
instructions.
Bioinformatics
Microarray data were normalized using median normalization
method. Pathway analysis of the gene expression data was
performed using the Gene Set Enrichment Analysis (GSEA),
which is able to detect coordinate changes in the expression of
groups of functionally related genes [50,51]. An enrichment score
(ES) was calculated for each gene set in GSEA and the statistical
significance of the ES was estimated by an empirical permutation
test using 1,000 gene permutations to obtain the nominal p-value.
GSEA software was downloaded from http://www.broad.mit.
edu/gsea/
Luciferase reporter assay
Cells were transiently transfected using the basic nucleofector kit
for primary mammalian neural cells (Amaxa biosystems) according
to the manufacturer’s instructions. Briefly, after trypsinization, cell
counting using hemocytometer, and centrifugation, ,5610
6 cells
were re-suspended in 100 ml of Basic Nucleofector Solution
(Amaxa biosystems), and transfected with 1 mg of reporter
plasmids (pTOPflash or pFOPflash), and 1 mg of internal control
pRL-TK; with or without 4 mg of dominant negative (DN)-TCF
Figure 4. Levels of b-catenin and phospho-b-catenin (p-b-catenin), and their subcellular localization. In HB1.F3, b-catenin is mainly
localized in nucleus (A), and p-b-catenin is not detected (B, C). In F3.Olig2, b-catenin is mainly localized in cytoplasm (A), and p-b-catenin is detected
and mainly localized in nucleus (B, C). The level of GSK3b, which phosphorylates b-catenin on Ser-33/Ser-37/Thr-41, is increased in F3.Olig2 (C).
Bar=50 mm
doi:10.1371/journal.pone.0003917.g004
Olig2-Induced Differentiation
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4 cells were
transferred to each well of a 24-well plate containing fresh, pre-
warmed DMEM and maintained for 48 hrs at 37uC and 5% CO2.
Then, the cells were lysed in lysis buffer, and 20 ml of each lysate
was monitored for luciferase activity using Dual-Luciferase
Reporter Assay System (Promega). Light units were measured
using Lmax II 384 (Molecular devices).
A control reporter, pRL-TK contains a herpes simplex virus
thymidine kinase promoter driving a Renilla luciferase gene, and
Renilla luciferase activity was used to normalize the results for
transfection efficiency. The reporter activities were shown as the
ratios of TOPflash to FOPflash luciferase activity from triplicate
experiments.
RT-PCR
RNA was isolated from six biological replicates from each group
using Qiagen RNeasy MiniKit (Qiagen), pooled, and subjected to
first-strand cDNA synthesis using Reverse Transcription System
(Promega, A3500) according to the manufacturer’s instructions.
Amplification was carried out at 94uC for 2 min, followed by 30
cycles at 94uC for 1 min, at appropriate annealing temperatures
for each primer for 1 min, and at 72uC for 1 min 30 s. Sequences
of primers used for RT-PCR are summarized in Supplementary
Table S1.
Immunoblot
Cell lysates were prepared with lysis buffer containing 7 M urea,
2 M thiourea, and 4% CHAPS. Equal amounts (25 mg) of protein
from each group were separated in 4–12% polyacrylamide gels
(Invitrogen) and transferred to nitrocellulose membrane (Millipore).
The primary antibodies used were anti-b-catenin (1:1000, #9562),
anti-phospho-pS33/pS37/pT41-b-catenin (1:1000, #9561), anti-
GSK3 (1:1000, #9315), anti-p-GSK3b (1:1000, #9336), and
anti-b-actin (1:1,000, #4967 ) from Cell Signaling Technology.
Immunofluorescent analysis
Cells were grown on Lab-Tek II chamber slide (Nalge Nunc
Int., Naperville, IL), rinsed in PBS, fixed in 4% paraformaldehyde
for 20 min, and rinsed again in PBS. The cells were incubated for
overnight at 4uC with following antibodies: b-catenin antibody
(1:200, Cell signaling, #9562); p-b-catenin antibody (1:200, Cell
signaling, #9561); Nestin antibody (1:100, Chemicon, MAB5326);
CD133 antibody (1:100, abcam, ab161518); O4 antibody (1:200,
Chemicon, MAB345); CNPase antibody (1:200, Chemicon,
MAB326); GFAP antibody (1:1,000, Chemicon, AB9598); S100
antibody ( 1:1,000, Kamiya biomedical company, MC-032). The
cells were rinsed in PBS and incubated for 1 h at room
temperature with Alexa fluor 594 goat anti rabbit IgG (1:500,
molecular probes Inc., A11012); Alexa fluor 594 goat anti mouse
IgG (1:500, molecular probes Inc., A11005); Alexa fluor 488
rabbit anti goat IgG (1:500, molecular probes Inc., A11078); Alexa
fluor 488 donkey anti rabbit IgG (1:500, molecular probes Inc.,
A21206). For counterstaining of cell nuclei cells were incubated
with DAPI (496-diamidino-2-phenylindole; 1 mg/ml, Sigma-Al-
drich) in H2O for 40 sec. After wash in PBS, coverslips were
mounted onto glass slides using Fluoroguard Antifade reagent
(Bio-Rad Laboratories, Hercules, CA), and examined under a
laser confocal fluorescence microscope (FV500, Olympus, Japan).
Figure 5. Dkk1 inhibits Wnt signaling in HB1.F3. A. TOPflash/FOPflash reporter assay shows that Dkk1 represses Wnt signaling in HB1.F3 in a
dosage-dependent manner. Data are means6S.D. of triplicate samples. B. Dkk1 represses the expression of c-myc, one of the target genes of Wnt
pathway, in HB1.F3 in a dosage-dependent manner. C. Dkk1 treatment induces the expression of oligodendrocytes markers (Olig2 and CNPase) in
HB1.F3.
doi:10.1371/journal.pone.0003917.g005
Olig2-Induced Differentiation
PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e3917Figure 6. Immunohistochemical staining of HB1.F3 or HB1.F3 with Dkk1 treatment for various markers of stem cell and
differentiated cells. Dkk1 induces differentiation of HB1.F3 into astrocytes, neurons and oligodendrocytes. Astrocyte markers (GFAP, S100),
oligodendrocyte markers (CNPase, O4), neuron markers (NeuroD, NeuN) and neural stem cell markers(Nestin, CD133) were double stained with DAPI
(blue) in HB1.F3 before (A, C, E, G ) and after (B, D, F, H ) Dkk1 treatment. Bar=50 mm
doi:10.1371/journal.pone.0003917.g006
Olig2-Induced Differentiation
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Figure S1 Phase contrast(DIC) and merged images of the
immunohistochemical staining of HB1.F3 or HB1.F3 with Dkk1
treatment for various markers of stem cell and differentiated cells.
Merged images of DAPI and astrocyte markers (GFAP, S100),
oligodendrocyte markers (CNPase, O4), neuron markers (NeuroD,
NeuN) and neural stem cell markers(Nestin, CD133) were
compared with DIC images in HB1.F3 before( A, C, E, G ) and
after( B, D, F, H ) Dkk1 treatment. Bar=50 mm
Found at: doi:10.1371/journal.pone.0003917.s001 (10.49 MB
TIF)
Table S1 GSEA details of Wnt pathway genes
Found at: doi:10.1371/journal.pone.0003917.s002 (0.06 MB
DOC)
Table S2 GSEA details of Wnt-responsive genes
Found at: doi:10.1371/journal.pone.0003917.s003 (0.05 MB
DOC)
Table S3 GSEA details of Wnt-responsive genes
Found at: doi:10.1371/journal.pone.0003917.s004 (0.05 MB
DOC)
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